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Abstract: Breast cancer is a complex, molecular disease, in which a number of cellular pathways 
involving cell growth and proliferation, such as the MAPK, RB/E2F, P13K/AKT/mTOR, and 
TP53 pathways, are altered. These pathways represent molecular mechanisms that are composed 
and regulated by various genes. The genes that are altered in terms of cell growth and proliferation 
include the oncogenes HER2, c-MYC, and RAS, the ER genes, and the genes for cell cyclin D1 
and E, and the tumor suppressor genes RB, TP53, and PTEN, and the breast cancer susceptibility 
genes BRCA1 and BRCA2. Although the nature of breast cancer is complex and has frustrated 
previous attempts at treatment or prevention, the elucidation of its molecular nature over the last 
several decades is now providing targets for effective therapies to treat the disease and hopefully 
one day to prevent it.
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At the beginning of the twentieth century, a number of theories were proposed 
to account for carcinogenesis (Marcum 2002). Of these, Boveri’s somatic muta-
tion theory became the predominant guiding theory (Boveri 1914; Varmus and 
Weinberg 1993). The current manifestation of the theory states that cancer is the 
result of sporadic and/or inheritable genetic mutations in somatic or germinal cells, 
respectively (Edler and Kopp-Schneider 2005; Schulz 2006; Wunderlich 2006). 
These mutations affect a number of cellular pathways, including the MAPK, 
RB/E2F, P13K/AKT/mTOR, and TP53 pathways, which are responsible for cell 
growth and proliferation (Hanahan and Weinberg 2000; Vogelstein and Kinzler 
2004; Schulz 2006).
Malignant breast cancer is a complex, molecular disease in which alterations 
take place in the genes that govern cell growth and proliferation (Sledge and Miller 
2003; Ingvarsson 2004). The predominant form of breast cancer is sporadic in 
nature, in which oncogenes – which are initially mutated – lead to uncontrolled 
cell proliferation (Kenemans et al 2004). Other genetic mutations, especially in 
tumor suppressor genes (TSGs), are then thought to lead to malignancy. Hereditary 
or familial breast cancer, which represents only 5%–10% of breast cancer cases, 
is controlled by inheritable mutations to susceptibility genes, among other genes 
(Pavelic  ´ and Gall-Trošelj 2001; Margolin and Lindblom 2006; Walsh and King 
2007).
The progression from normal to malignant breast tissue is not completely 
understood today but enough of the process is understood to develop therapies 
that target the molecular changes that occur during breast carcinogenesis (Osborne 
et al 2004; Schulz 2006). Traditional chemotherapy for treatment of cancer 
suffers from two major problems. First, it is non-speciﬁ  c in that the drugs used to 
treat patients cannot distinguish between tumor and normal cells. This inability to Biologics: Targets & Therapy 2007:1(3) 242
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distinguish between the two types of cells leads to a second 
problem – toxic side effects that are often more debilitating 
than the disease. A new approach to treatment – targeted 
therapy – attempts to resolve these problems by the rational 
design of drugs that speciﬁ  cally target cancer cells (Segota 
and Bukowski 2004; Seynaeve and Verweij 2004; Garrett 
2005; Pegram et al 2005; Sledge 2005; Sharkey and 
Goldenberg 2006).
Over the past decade, targeted therapy has offered 
particularly promising means to treat breast cancer 
(Bange et al 2001; Sledge 2001; Kaklamani and O’Regan 
2004; Osborne et al 2004; Gasparini et al 2005; Hobday 
and Perez 2005; Johnson and Seidman 2005; Tripathy 
2005; Muss 2006). In this review, a limited selection of 
the genes responsible for cell growth and proliferation, 
including oncogenes, TSGs, and susceptibility genes, 
are examined and discussed, especially with respect to 
targeted therapies. The paper concludes with a discussion 
of the challenges facing basic and clinical research to 
develop effective and safe treatment of a disease that is 
estimated to kill 40,460 women in 2007, in the USA alone 
(Jemal et al 2007).
Oncogenes
Oncogenes are the ﬁ  rst “cancer” genes to be well studied 
molecularly and represent alterations of proto-oncogenes 
that are involved in the normal regulation of cell growth and 
proliferation (Varmus and Weinberg 1993; Macdonald et al 
2004; Schulz 2006). Alteration of these genes results in what 
is termed gain-in-function, ie, cell growth and proliferation. 
These genes are responsible for sending the cell from a resting 
state into cell division. In other words, they are comparable 
to stepping on the accelerator of an automobile (Weinberg 
1998).
Oncogenes are dominant, since a single “hit” or 
alteration is required to activate them. For example, they 
may be ampliﬁ  ed or their protein products overexpressed 
and therefore more of the product is present; or, they may 
be mutated to enhance the function of the protein (Osborne 
et al 2004; Schulz 2006). They are responsible for sporadic 
cancers, which account for the majority of breast cancers 
(Macdonald et al 2004; Schulz 2006). Although oncogenes 
are involved in the initiation of cancer, they appear not to 
be as important in the latter stages (Harris 2005). There 
are a host of oncogenes involved in the development of 
breast cancer, with HER2, c-MYC, and RAS, being more 
intensely studied (Table 1). Besides these oncogenes, the 
genes for estrogen receptors (ERs), cyclin D1 and E, and 
cyclin-dependent kinases 2 and 4/6 are also important in 
breast cancer formation (Table 1).
HER2
The HER2 gene (human epithelial receptor 2, also known 
as c-neu or c-erbB2) belongs to the HER gene family, 
with epidermal growth factor receptor (EGFR) or HER1 
being the ﬁ  rst discovered (Ross and Fletcher 1998; Ross 
et al 2004a). The HER2 gene is located on chromosome 
17q12 (Kaptain et al 2001). The HER2 protein is a 185 
kDa transmembrane tyrosine kinase growth factor receptor 
and shares structural homology with the other HER 
family members, including an extracellular region, a 
transmembrane region, and a cytoplasmic region (Klapper 
et al 2000; Kaptain et al 2001; Jorissen et al 2003; Bazley 
and Gullick 2005). The extracellular region at the amino 
terminus is glycosylated and contains two ligand-binding 
domains and two cysteine-rich domains that are critical for 
receptor dimerization. The hydrophobic transmembrane 
region makes a single pass through the cell membrane. The 
cytoplasmic region contains the protein tyrosine kinase 
domain and six tyrosine residues at the carboxy terminus 
that are available for phosphorylation.
Around a dozen ligands, including EGF, neu or heregu-
lin, and TGFα, bind to the HER receptor family; however, 
there is no known ligand speciﬁ  c for HER2 or the receptor is 
unable to bind a ligand (Harris et al 2003; Ross et al 2004a; 
Bazley and Gullick 2005). Upon ligand binding the receptors 
form either homodimers or heterodimers and are activated 
by phosphorylating the cytoplasmic tyrosines. HER2 forms 
heterodimers, especially with HER1 and HER3, which is 
responsible for tumor formation (Holbro et al 2003; Chan 
et al 2006). The activated receptor dimers are involved via 
signal transduction in a variety of cellular pathways, such 
as MAPK and P13K/AKT/mTOR pathways (Bazley and 
Gullick 2005; Chan et al 2006). Functionally, the HER 
receptor family is involved in cell growth and proliferation, 
angiogenesis, altered cell-cell interactions, increased cell 
Table 1 Oncogenes
Gene Location  Protein  Function
HER2  17q12  185 kDa kinase  Growth factor receptor
c-MYC  8q24  62 kDa nuclear  Transcription factor
   phosphoprotein
HRAS  11p15.5  21 kDa GTPase  Signal transduction
CCND1  11q13  34 kDa cyclin D1  Regulates CDK4/6
Cyclin E  19q12  50 kDa cyclin E  Regulates CDK2
ERα  6q25.1  67 kDa protein  TranscriptionBiologics: Targets & Therapy 2007:1(3) 243
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motility, metastasis, and resistance to apoptosis (Osborne 
et al 2004; Sunpaweravong and Sunpaweravong 2005).
The HER2 gene is ampliﬁ  ed in 20%–30% of breast cancer 
cases or the HER2 protein is overexpressed in roughly the 
same percentage of cases, although there are cases in which 
the protein is overexpressed while the gene is not ampliﬁ  ed 
(Berns et al 1995; Kaptain et al 2001; Ross et al 2003; Hudis 
2007; Magniﬁ  co et al 2007). HER2 overexpression is found 
almost exclusively in breast cancer of ductal origin rather 
than lobular origin (Klapper et al 2000; Ross et al 2004a). 
It is also associated with higher recurrence rates and lower 
response to chemotherapy or hormone therapy, with overall 
poor prognosis and survival (Kaptain et al 2001; Ross et al 
2004a). Moreover, 15% of breast cancer cases expressed 
lower levels of the HER2 protein than normal breast tissues 
and exhibited higher grade tumors than cases in which the 
protein is overexpressed (Tovey et al 2006). Overexpression 
of other members of the HER family is also observed in breast 
cancer cases, with HER1, HER3, and HER4 overexpressed 
in 16.4%, 17.5%, and 11.9% of the cases, respectively 
(Witton et al 2003). Interestingly overexpression of HER4 
conferred an increased survival rate, although the reason for 
this phenomenon is unclear and requires further evidence to 
support it.
Given its prominence in the activation of around a 
half dozen genetic pathways involved in cell growth and 
proliferation HER2 is a major focus of research in terms 
of targeted therapy, including monoclonal antibodies, 
kinase inhibitors, and antisense oligonucleotides (Osborne 
et al 2004; Ross et al 2004a; Hobday and Perez 2005). 
Trastuzumab is the most celebrated monoclonal for breast 
cancer treatment, ﬁ  rst tested in clinical trials in the mid 
to late 1990s (Baselga et al 2006; Piccart-Gebhart 2006; 
Hudis 2007; Nahta and Esteva 2007). It is a humanized 
monoclonal antibody, originally produced in mice, which 
recognizes the extracellular domain. It is particularly effec-
tive in patients who overexpress HER2, with response rates 
ranging from 12% to 34%, and is commonly used in con-
junction with chemotherapy or at least one cytotoxic drug 
except anthracycline (due to cardiomyopathy). Trastuzumab 
binds to HER2 and works through multiple mechanisms, 
including, for example, inhibition of heterodimer forma-
tion, potentiation of chemotherapy, and enhanced cell 
apoptosis.
Pertuzumab is another monoclonal antibody that inhibits 
the formation of heterodimers by recognizing an extracel-
lular region distinct from trastuzumab and is currently 
being tested clinically (Cox et al 2006; Meric-Bernstam 
and Hung 2006; Walshe et al 2006). It may be effective 
in combination therapy with agents such as trastuzumab. 
Lapatinib is a large-head group quinazoline, reversible 
inhibitor of the tyrosine kinase domain of HER1 and HER2 
(Burris 2004; Meric-Bernstam and Hung 2006). Preliminary 
data from clinical trials reveal that 8% of refractory meta-
static breast cancer patients have a complete response to 
the inhibitor (Moy and Goss 2006). Moreover, lapatinib is 
particularly effective in combination with either capecitabine 
or trastuzumab, eg, the average time to progression was 
8.4 months for the combination of lapatinib and capecitabine 
but only 4.4 months for capecitabine alone (Geyer et al 
2006; Konecny et al 2006). Antisense oligonucleotides to 
various HER2 domains also offer promise for breast cancer 
targeted therapy, by downregulating HER2 expression and 
by sensitizing breast cancer cells to chemotherapy (Yang 
et al 2002, 2003).
c-MYC
The c-MYC gene, the cellular homolog to the viral oncogene 
v-MYC, is located on chromosome 8q24 (Ryan and Birnie 
1996; Jamerson et al 2004). The c-MYC gene product is 
a nuclear phosphoprotein, with three isoforms: c-MYC1, 
c-MYC2, and c-MYCS (Henriksson and Luscher 1996; Liao 
and Dickson 2000; Pelengaris and Khan 2003; Jamerson 
et al 2004). The predominant isoform is c-MYC2, which is a 
62 kDa protein. Its amino terminus contains the MYC box I 
and box II elements responsible for transcriptional regulation, 
while its carboxy terminus contains basic, helix-loop-helix 
and leucine zipper motifs that are involved in DNA binding 
and in heterodimerization with the transcription factor MAX. 
The heterodimer MYC-MAX binds to the E box (CACGTG) 
regulatory element of growth-related genes thus inducing 
transcription. c-MYC1’s amino terminus is slightly extended, 
while c-MYCS’s amino terminus is truncated and missing 
MYC box I.
c-MYC is normally expressed only during cell division 
and accelerates the cell’s entry into the S phase of the cell 
cycle, especially through induction of cyclin E-CDK2 activity 
(Pelengaris and Khan 2003; Dang et al 2006). The c-MYC 
gene product functions as a nuclear transcription factor that 
is involved in the regulation of an extensive network of genes 
that represents around 15% of human genes. These genes 
are responsible for a variety of cellular processes, including 
proliferation, apoptosis, differentiation, and metabolism 
(Oster et al 2002; Pelengaris and Khan 2003; Jamerson 
et al 2004; Dang et al 2006). Interestingly, c-MYC not only 
stimulates cell proliferation but also cell apoptosis. To date, Biologics: Targets & Therapy 2007:1(3) 244
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this paradox is not fully understood or explained (Pelengaris 
and Khan 2003; Dang et al 2006). c-MYC also exhibits dual 
function, in terms of both transactivation and transrepression 
of transcription. Transactivation requires the presence of 
MYC box I, while transrepression MYC box II.
Meta-analysis of the published literature reveals that 
c-MYC is overexpressed three-fold or greater in 1%–94% 
of breast cancer cases, with an average of 15.5% (Liao and 
Dickson 2000). Although there is also considerable varia-
tion in the oncogene’s ampliﬁ  cation, from 4% to 52%, cases 
that contain ampliﬁ  ed MYC exhibit poor prognosis (Guerin 
et al 1988; Liao and Dickson 2000; Osborne et al 2004). The 
overexpression of c-MYC often precedes gene ampliﬁ  cation 
and may result from enhanced transcript or protein stability 
(Liao and Dickson 2000). Interestingly, ampliﬁ  cation of 
c-MYC is positively correlated with ampliﬁ  cation of HER2 
(Gaffey et al 1993; Liao and Dickson 2000). Although 
there is consensus concerning the role of c-MYC in breast 
carcinogenesis, most researchers agree that other genes are 
also required. For example, c-MYC-induced breast cancer 
is correlated with spontaneous KRAS2 mutation (D’Cruz 
et al 2001).
Use of antisense oligonucleotides to speciﬁ  c regions of 
c-MYC demonstrates that the expression of the oncogenic 
protein and proliferation of cells overexpressing the oncogene 
are signiﬁ  cantly reduced by 30% (Watson et al 1991; Carroll 
et al 2002). However, application of antisense technology 
has not been unproblematic. Recently, RNA interference 
technology has been developed to silence gene expression 
in mammalian cells (Sui et al 2002). Brieﬂ  y, dsRNAs are 
used to generate short interfering RNAs (siRNAs) that are 
incorporated into a nuclease complex that binds speciﬁ  cally 
to the targeted mRNA and cleaves it. Knockdown of c-MYC 
in a breast cancer cell line using a short hairpin transcript 
corresponding to c-MYC mRNA nt 1906–1926, resulted in 
an 80% reduction in c-MYC gene expression (Wang et al 
2005). Also, tumor generation in nude mice was inhibited for 
two months. Finally, use of a triplex-forming oligonucleotide 
to bind duplex DNA resulted in around 40% reduction of 
c-MYC expression in breast cancer cells (Christensen et al 
2006). These approaches are heralded to provide future 
beneﬁ  ts for targeting breast cancer therapeutically.
RAS
The RAS genes are located on three separate chromosomes 
(Giehl 2005). The ﬁ  rst is on chromosome 11p15.5 and 
transcribes HRAS kinase. The next gene is on chromosome 
12p12.1 is responsible for two splicing variants, KRAS4A 
and KRAS4B. The ﬁ  nal gene is on chromosome 1p13.2 and 
encodes for NRAS kinase. The RAS kinases are members of 
a superfamily of 21 kDa monomeric GTPases (Giehl 2005; 
Schulz 2006). The kinases contain three domains, with two 
highly conserved catalytic domains. The third is located 
at the carboxy terminus and is a cell membrane targeting 
domain that is highly variable, which is composed of a linker 
region that contains nuclear trafﬁ  cking signals and an anchor 
region that connects the protein to the cell membrane (Giehl 
2005). During posttranslational modiﬁ  cations, the anchor 
region undergoes prenylation of a CAAX motif (C stands 
for cysteine, A for an aliphatic amino acid, and X for any 
amino acid) and then palmitoylation of two cysteines for 
HRAS and one cysteine for NRAS and KRAS4A (Hancock 
2003; O’Regan and Khuri 2004; Giehl 2005). KRAS4A is 
not palmitoylated but contains six contiguous lysines. The 
modiﬁ  ed RAS kinases are then embedded in the cytoplasmic 
side of the plasma membrane.
The RAS kinases are activated through binding of growth 
factors to receptors, like the receptor tyrosine kinases (Giehl 
2005; Schulz 2006). Activation occurs with the exchange 
of GTP for GDP. The activated RAS protein then phos-
phorylates a number of secondary messengers involved in a 
variety of cellular pathways that function in cell apoptosis, 
differentiation, motility, and proliferation. One of the more 
important pathways is the RAF/MEK/ERK pathway, which 
is one of several MAPK pathways (Schulz 2006). RAS 
phosphorylates the RAF serine/threonine kinases, which 
in turn phosphorylate the MEK 1 and 2 kinases, which 
in turn phosphorylate ERK 1 and 2. Phosphorylated ERK 
translocates to the nucleus, where it interacts with various 
transcription factors involved in cell proliferation. Another 
important pathway is the P13K/AKT/mTOR pathway. RAS 
phosphorylates P13K, which in turn phosphorylates phos-
phatidyl inositol resulting in the production of PIP3. PIP3 is a 
second messenger that is involved in the activation of other 
downstream molecules, such as the kinase AKT and mTOR. 
Activation of this pathway results in cell survival through 
the inhibition of cell apoptosis.
Analysis of breast tumors demonstrates that RAS is only 
associated with less than 5% of breast cancer cases (Clark 
and Der 1995; Eckert et al 2004). Moreover, in those cases in 
which it participates the oncogene appears not to be mutated 
as is the case in other RAS tumors (Eckert et al 2004). Rather, 
RAS is hyperactive because of overexpression of EGF and/or 
HER2 (Stevenson et al 1999; von Lintig et al 2000; Eckert 
et al 2004). However, those cases that involve RAS exhibit 
poor prognosis (Field and Spandidos 1990). Analysis of Biologics: Targets & Therapy 2007:1(3) 245
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breast cancer cell lines, on the other hand, reveals RAS gene 
mutations (von Lintig et al 2000; Hollestelle et al 2007). 
Point mutations are observed in 7 of 40 cell lines, with the 
preponderance of mutations in KRAS (Hollestelle et al 2007). 
Recently, the effector pathway(s) for cell apoptosis in breast 
cancer may not be the RAF/MEK/ERK or the P13K/AKT/
mTOR pathways but another, such as the Ral or Rac path-
ways (Eckert et al 2004). A modiﬁ  ed breast cancer cell line in 
which HRAS and NRAS are constitutively expressed reveals 
that HRAS activation of the Rac-MKK3/6-p38 pathway may 
play a role in breast cancer metastasis (Shin et al 2005).
RAS offers several molecular targets for therapeutic 
intervention. The ﬁ  rst step in RAS activation involves the 
transfer of a prenyl group to RAS by farnesyl transferase. 
A number of inhibitors to the enzyme have been shown to 
inhibit its activity and thereby to inhibit the growth of a 
number of tumor lines (Head and Johnston 2004; O’Regan 
and Khuri 2004). The ﬁ  rst generation of inhibitors, such as 
L-744,832 and FTI-277, were successful and eventually led to 
a second generation of inhibitors, R115777 and SCH66336. 
In preclinical trials, R115777 inhibits by up to 85% the 
proliferation of breast cancer cell lines in vitro and growth 
of tumors in vivo (Wärnberg et al 2006). Phase II trials 
demonstrated limited clinical efﬁ  cacy of R115777 in treating 
cases of advanced breast cancer, with 10% of patients having 
a partial response (Johnston et al 2003). Recently clinical tri-
als are underway to examine the synergistic effects of farne-
syl transferase inhibitors with other drugs, such as tamoxifen 
or the taxanes (Head and Johnston 2004; Lebowitz et al 
2005). Similar trials are underway with SCH66336 (Basso 
et al 2005; Marcus et al 2005). Antisense oligonucleotides 
are also promising, especially when combined with other 
drugs (Adjei et al 2003).
Cyclins D1 and E
The cell cycle is composed of a variety of phases that result 
in cell growth and replication (Schafer 1998; Israels and 
Israels 2000). Cells in the quiescence G0 phase are shuttled 
into the G1 phase in which they prepare to enter the S phase 
of DNA replication. After the S phase, the cells enter the 
G2 phase prior to mitosis or the M phase, during which the 
cells undergo division. The cell cycle and its various phases 
are closely regulated in a dynamic fashion, by a variety of 
factors (Tyson et al 2002). The ﬁ  rst are the cyclin-dependent 
kinases (CDKs), which are the “engines” that power cell 
cycle events (Morgan 1997). They constitute a family 
of serine/threonine protein kinases, with around a dozen 
members of which around half are involved in the cell cycle. 
While the levels of CDKs do not oscillate during cell cycle 
events, cyclins, which bind and activate the CDKs, do and 
provide one level of regulation (Johnson and Walker 1999; 
Murray 2004). Another level of regulation involves CDK 
inhibitors (CKIs), of which there are a little over a half-dozen 
divided into two families, INK4 and Cip/Kip families (Soos 
et al 1998). CKIs are critical for inactivating CDK/cyclin 
holoenzymes. Interestingly, recent gene targeted studies on 
mouse development challenge the standard “CDK-centric” 
paradigm (Sherr and Roberts 2004; Malumbres 2005; Sán-
chez and Dynlacht 2005).
A key junction in the regulation of the cell cycle vis-à-vis 
carcinogenesis is the transition from the G1 to the S phase 
(Sherr 1996, 2000; Sandal 2002; Park and Lee 2003). Cyclins 
D1 and E, the G1 cyclins, are critical regulatory elements in 
the transition of the cell from the G1 phase to the S phase. 
Cyclin D1 is upregulated by growth factors, like EGF and 
estrogen, and binds to CDK4/6 and partially phosphorylates 
RB, which in turn releases E2F. E2F is a transcription factor 
that targets the cyclin E gene and upregulates it. The cyclin 
E gene product binds to CDK2 and forms the cyclinE-CDK2 
holoenzyme, which then completes the phosphorylation 
and inactivation of RB. RB is the “master switch” that is 
responsible for turning on or off the cell cycle (Sherr 1996, 
2000). Finally, the CKIs p21 and p27 also play an important 
regulatory role in the transition from G1 to S (Sherr and 
Roberts 1999). Cancer, including breast cancer, is then a 
result of deregulation of the genes involved in cell cycle 
control (Lodén et al 2002; Vermeulen et al 2003; Sutherland 
and Musgrove 2004; Caldon et al 2006).
The cyclin D1 gene, CCND1 (PRAD1), is located on 
chromosome 11q13 and is composed of ﬁ  ve exons (Fu 
et al 2004). It encodes for a 34 kDa protein that contains 
several domains (Arnold and Papanikolaou 2005). At the 
amino terminus is a RB binding domain. Cyclin D1 also 
contains a highly conserved cyclin box, which is composed 
of around 100 amino acids and is responsible for binding 
CDKs. A common polymorphism (A/G) is located at 870 nt 
and is associated with a slicing variant of cyclin D1, which 
contains intron 4 but in which exon 5 is deleted. Cyclin D1 
is overexpressed in greater than 50% of breast cancer cases 
but its gene is only ampliﬁ  ed in 13%–20% of breast cancer 
cases (Arnold and Papanikolaou 2005; Roy and Thompson 
2006). When cyclin D1 is overexpressed it shortens the 
time spent in G1 and allows more cells to enter the S phase, 
which relies on both CDK-dependent and CDK-independent 
mechanisms. Its overexpression is associated with an aggres-
sive form of breast cancer and poor prognosis. The cyclin D1 Biologics: Targets & Therapy 2007:1(3) 246
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gene is co-ampliﬁ  ed with the HER2 and c-MYC genes and is 
associated with ER positivity. To date, there are no targeted 
therapies based on cyclin D1, although it is believed to hold 
great promise for future therapeutic intervention (Arnold and 
Papanikolaou 2005).
The cyclin E gene is located on chromosome 19q12 and 
encodes for a 50 kDa protein, along with almost a dozen 
splicing variants – some of which are incapable of activat-
ing CDK2 (Möröy and Geisen 2004). Cyclin E possesses 
the conserved cyclin box for CDK2 binding, as well as a 
CKI binding site. In addition it contains speciﬁ  c proteolytic 
sites at the amino terminus that are sensitive to elastase 
degradation, generating ﬁ  ve isoforms that exhibit greater 
holoenzyme activity than the native isoform (Akli and 
Keyomarsi 2003; Harwell et al 2004; Hunt and Keyomarsi 
2005). Interestingly, these elastase-generated isoforms are 
only found in cancer cells and not in normal cells. Although 
cyclin E is overexpressed in breast cancer, by as much as 
64-fold in some breast cancer cell lines, it is rarely ampliﬁ  ed 
and is not overexpressed when cyclin D1 is overexpressed 
(Lodén et al 2002; Hunt and Keyomarsi 2005). Cyclin E 
overexpression is associated with poorly differentiated 
tumors and ER negativity; however, it also reduces inﬁ  ltra-
tive growth of breast carcinoma (Berglund and Landberg 
2006). Its overexpression is also associated with genomic 
instability (Akli and Keyomarsi 2004; Möröy and Geisen 
2004). Cyclin E has yet to be developed in terms of targeted 
therapy, although preliminary studies with elatase inhibitors 
appear promising (Akli and Keyomarsi 2003; Hunt and 
Keyomarsi 2005).
Besides cyclins, CDKs have also been a target for 
therapeutic development (Senderowicz 2003; Vermeulen 
et al 2003; Osborne 2004; Collins and Garrett 2005). Two 
approaches are taken: a direct approach in which CDKs’ 
catalytic sites, especially the ATP-binding site, are targeted 
and an indirect approach in which the upstream pathways 
that govern CDKs are targeted. For the direct approach a 
number of small molecular weight inhibitors have been 
developed that are speciﬁ  c for particular CDKs, such as 
roscovitine, purvalanol, and nitrosopirimidines, which tar-
get CDK1, 2, and 5, and indolocarbazoles and PD0183812, 
which target CDK4, and ﬂ  avopiridol and UCN-01, which 
target CDKs nonspeciﬁ  cally. For example, roscovitine 
inhibits by 50%–70% the proliferation of human breast 
carcinoma cells (We  ˛sierska-G dek et al 2003). A number 
of strategies have been developed for the indirect approach, 
including the overexpression of endogenous CKIs through 
gene therapy and small molecular weight molecules like 
lovastatin and rapamycin, the depletion of cyclins and CDKs 
through antisense oligonucleotides and small molecular 
weight molecules like tamoxifene and the retinoids, and the 
modulation of the proteasome mechanism like PS341. For 
example, lovastatin at 50 μM inhibits the proliferation of 
human breast cancer cell line MCF-7, by up to 90% (Seeger 
et al 2003). Overall, these approaches are in various stages 
of clinical trials and use, with varying degrees of efﬁ  cacy 
and safety.
Estrogen and its receptor
Estrogen is a generic term for a family of sex hormones 
that are critical for the mammalian estrous cycle (Messinis 
2006). There are three main classes of estrogens: estradiol 
(17β-estradiol), estrone, and estriol. Estrogen synthesis takes 
place predominantly in the ovaries in premenopausal women 
and to a lesser extent in extragonadal tissues, including 
breast tissue, which, along with other extragonadal tissue, 
is its source in postmenopausal women (Huang et al 2005; 
Jordan and Brodie 2007). It begins with the synthesis of 
C-19 androgens from cholesterol in ovarian theca interna cells. 
Upon entrance into ovarian granulosa cells the androgens 
are aromatized by an aromatase complex, consisting of 
cytochrome P450 hemoprotein and NADPH-cytochrome P450 
reductase – a ﬂ  avoprotein that is part of a larger cytochrome 
superfamily. Three hydroxylation steps are postulated in the 
synthesis of estradiol from testosterone and of estrone from 
androstenedione. Finally, estrogens appear to enhance their 
own synthesis through a feed-forward mechanism involving 
prostaglandin synthesis (Frasor et al 2003).
There are two types of estrogen receptors (ERs), which are 
the product of two separate genes (Kenemans et al 2004). The 
ERα gene is located on chromosome 6q25.1, while the ERβ 
gene is located on chromosome 14q22–24. Although there 
are two different ER genes, their products share considerable 
structural and functional homology (Kuiper et al 1996). Both 
ERs contain six structural domains (domains A-F) that com-
pose several functional domains (Herynk and Fuqua 2004). 
A transactivation domain is associated with amino terminus 
domains A and B, which bind various regulatory elements 
that modulate ER-mediated transcriptional activity. A DNA 
binding domain is associated with domain C, which contains 
two zinc ﬁ  nger motifs. This domain binds to the promoters of 
ER-targeted genes. The ER dimerization domain is divided 
between the C and E domains, along with an area at the 
carboxy terminus. The nuclear localization signal is located 
in domain D, which also contains the hinge region. Finally, 
domains E and F contain a ligand-binding domain and another Biologics: Targets & Therapy 2007:1(3) 247
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transactivation domain. Both ERs also exhibit a variety of 
splicing variants (Herynk and Fuqua 2004).
Estrogen is a potent mitogenic hormone that is critical 
not only in breast development but also in its carcinogenesis, 
although there is debate about its role in breast cancer initia-
tion (Foster et al 2001; Wren 2004; Russo and Russo 2006). 
The ERα isoform is the predominant agent of mitogenic activ-
ity in breast tissue and is overexpressed in the early stages of 
breast cancer (Hayashi et al 2003; Hewitt et al 2005). Around 
two-thirds of breast cancer tissue expresses higher ER levels 
than normal tissue (Ideka and Inoue 2004). Estrogen binds 
to ERα to form a stable receptor dimer that is then phos-
phorylated inducing a conformational change, which thereby 
exposes a DNA-binding domain and transcriptional activation 
domains (Butt et al 2005). The dimer binds to target genes 
involved in phosphorylation of RB, especially both c-MYC 
and cyclins D1 and E (Roy and Thompson 2006).
Growth factors, such as EGF, IGF-I, and TGFα, also 
bind ER and lead to mitogenic activity in breast cancer 
cells (Butt et al 2005). ER and HER2 pathways also share 
contact or “cross-talk” during breast tumorigenesis (Sledge 
and Miller 2003). The role of ERβ in the development of 
breast cancer is unclear, although the ratio of ERα to ERβ 
is important in breast carcinogenesis (Cullen et al 2001; 
Herynk and Fuqua 2004). Finally, breast cancer tissue can 
be either ER-positive or ER-negative, with the ER-positive 
tumors forming a unique molecular subgroup (Perou et al 
2000). ER-negative tumors are associated with an aggressive 
form of the disease and consequently with poor prognosis 
(Rochefort et al 2003).
Antihumoral therapy is composed of antiestrogens 
to counteract the effects of estrogens on breast tissue, 
especially as antagonists to ERs (Huang et al 2005; Gao and 
Liu 2007). Type I antiestrogens, also known as selective 
estrogen receptor modulators (SERMs), are non-steroidal 
inhibitors, including tamoxifen, toremifene, and raloxi-
fene. These antiestrogens are widely used because they do 
not bind ERs indiscriminately; rather, they are partially 
selective in their binding speciﬁ  city and thereby protec-
tive against estrogen-associated bone loss (Jordan 2007). 
Type II antiestrogens include antagonists that are steroidal 
derivatives of estrogen, eg, ICI 164,384 and ICI 182,780. 
The binding of both types of antiestrogens causes a confor-
mational change in ER’s carboxy terminus. Unfortunately 
many patients become resistant to antiestrogen therapy. The 
mechanism of resistance is not completely understood; but 
the standard protocol is to switch to an estrogen-deprivation 
therapy, such as aromatase inhibitors (Huang et al 2005).
The aromatase complex represents an attractive 
target for therapeutic development, since the synthesis of 
estrogen represents the ﬁ  nal step in its synthetic pathway. 
Consequently, estrogen synthesis can be specifically 
inhibited without compromising the synthesis of other sex 
hormones (Jordan and Brodie 2007). However, the role of 
estrogens in other tissues besides breast cancer tissue makes 
the use of these inhibitors problematic since they create a 
“no estrogen state” (Huang et al 2005; Jordan and Brodie 
2007). Aromatase inhibitors (AIs) represent a very successful 
targeted therapy for breast cancer in postmenopausal women 
(Altundag and Ibrahim 2006).
There are two types of AIs, which are currently in 
their third generation (Huang et al 2005; Altundag and 
Ibrahim 2006). Type I inhibitors, such as exemestane, 
mimic the binding of the androgen substrate and thereby 
bind covalently and irreversibly to aromatase. Type II 
inhibitors, such as letrozole, are non-steroidal in nature 
and bind irreversibly to aromatase’s catalytic site. Recent 
studies demonstrate that AIs are effective as or even more 
effective than tamoxifen and are being administered as 
the primary adjuvant therapy instead of using it after 
tamoxifen as previously done (Altundag and Ibrahim 
2006). For example, letrozole was better in clinical studies 
than tamoxifen with respect to time to treatment failure, 
9.4 months versus 6.0 months on average respectively 
(Mouridsen et al 2003).
Tumor suppressor genes
While in general oncogenes promote cell growth and prolif-
eration, tumor suppressor genes (TSGs) inhibit them (Varmus 
and Weinberg 1993; Macdonald et al 2004; Schulz 2006). 
Alteration of these genes results in what is termed loss-of-
function, ie, cell quiescence, which leads to cell growth and 
proliferation. These genes are responsible for stopping the 
cell from dividing during cell division, especially if DNA is 
damaged during its replication (Motoyama and Naka 2004). 
In other words, they represent stepping on the brake of an 
automobile (Weinberg 1998).
In stopping cell division, TSGs also maintain the 
integrity of the cell’s genome and therefore function as a 
competent automobile mechanic (Vogelstein and Kinzler 
2004). Because of their functions in stopping the cell from 
dividing or in ensuring the DNA is not damaged, TSGs are 
often called gatekeepers or caretakers, respectively (Kinzler 
and Vogelstein 1997; MacLeod 2000). As such, they are 
important in maintaining the genome’s stability and integrity 
(Sherr 2004).Biologics: Targets & Therapy 2007:1(3) 248
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TSGs are recessive and require two “hits” in order to 
inactivate them (Knudson 1971). For example, they may be 
deleted physically or lost via recombination; or, they may be 
mutated or their promoter hypermethylated (Schulz 2006). 
TSGs are responsible for many hereditary cancers, such as 
the eye tumor retinoblastoma, although they are also neces-
sary for the development of sporadic cancers (Macdonald 
et al 2004; Schulz 2006). Because of their role in hereditary 
cancer, they are called susceptibility genes and act in a domi-
nant fashion (Macdonald et al 2004). There are several TSGs 
involved in the development of breast cancer, including RB, 
TP53, and PTEN, and the susceptibility genes BRCA1 and 
BRCA2 (Table 2). In general, treatment development based 
on TSGs presents a greater challenge than that based on 
oncogenes because TSGs represent loss-of-function rather 
than gain-of-function.
RB
The retinoblastoma (RB) gene is located on chromosome 
13q14 and is made up of 27 exons (Whyte 1995; Claudio 
et al 2002; Macdonald et al 2004; Du and Pogoriler 2006). 
The gene product, RB or p105, is a 105 kDa nuclear 
phosphoprotein, which contains no catalytic site and binds 
weakly and non-speciﬁ  cally to DNA. It contains well over 
a dozen possible phosphorylation sites, especially within 
the amino and carboxy termini. The RB protein shares 
conformational homology with RBL1 or p107, located 
on chromosome 20q11, and with RBL2 or p130, located 
on chromosome 16q12. This protein family is called the 
“pocket” proteins, since they contain a highly conserved 
pocket region for binding cellular proteins. RB protein 
contains an A domain (exons 11–17) and a B domain (exons 
20–23), separated by a short spacer (exons 18 and 19). The 
A/B domain makes up the small pocket region and, along 
with the carboxy terminus, makes up the large pocket 
region. These regions are responsible for binding various 
proteins and have at least two protein binding sites, one 
for E2F proteins (A/B domain interface) and another for 
proteins containing an LXCXE motif (B domain), which 
are functionally distinct from one another (Chau et al 2006). 
The spacer between the A and B domains for RBL1 and 
RBL2 binds cyclins A and E, while the PB spacer is too 
short to bind proteins.
The RB protein binds over 110 cellular proteins that 
can be divided into three classes (Morris and Dyson 
2001). The ﬁ  rst includes kinases, and their regulators, and 
phosphatases, the next class transcriptional regulators, and 
the ﬁ  nal class miscellaneous proteins that are involved in 
disparate functions such as cell cycle regulation and DNA 
replication. These proteins function to limit cell growth and 
proliferation, to amplify cell differentiation, and to restrain 
cell apoptosis (Morris and Dyson 2001; Zheng and Lee 
2001; Knudsen and Knudsen 2006). The most well studied 
protein that binds to the large pocket of RB belongs to 
the transcriptional regulator E2F family, which makes up 
the RB/E2F pathway (Dyson 1998; Macdonald et al 2004). 
The E2F family consists of eight family members, divided 
into four groups (Du and Pogoriler 2006). The ﬁ  rst consists 
of E2F1-3 and is called the “activating E2Fs,” since members 
of this class bind preferentially to RB and are responsible for 
promoting cell division. The second class consists of E2F4 
and 5 and is called “repressive E2Fs,” since its members 
bind preferentially to RBL1 and 2 and inhibit cell division. 
The E2F family binds to the two members of the DP family 
to form a heterodimer that then binds preferentially to RB 
family members.
RB or its pathway is altered in roughly 80% of human 
cancer cases, making it a very important factor in carci-
nogenesis (Schultz 2006). Loss of RB activity is present 
in about one-third of sporadic breast cancer cases and has 
a negative impact on patient outcome and response to 
treatment (Ross et al 2004b; Bosco et al 2007). RB loss 
in breast cancer occurs from chromosomal deletion, func-
tional inactivation through cyclins A or E overexpression, 
intragenic mutation, and transcriptional silencing such as 
promoter hypermethylation (Oesterreich and Fuqua 1999; 
Bièche and Lidereau 2000; Oliveira et al 2005). Interest-
ingly, 20% of breast cancer cases contain truncated muta-
tions of RB1CC1, an upstream regulator of RB expression 
(Chano et al 2002). Although RB alteration is important 
in breast cancer, studies with mammary epithelial cells 
revealed that alterations in other genes like TP53 are also 
required for tumor initiation and progression (Simin et al 
2004). To date, no targeted therapies for RB alterations 
have been developed, although reintroduction of RB into 
breast cancer cells resulted in growth suppression (Stoff-
Khalili et al 2006). And ﬁ  nally, RB modiﬁ  es the response 
of breast cancer cells to tamoxifen chemotherapy because 
Table 2 Tumor suppressor genes
Gene Location  Protein  Function
RB  13q14  105 kDa nuclear phosphoprotein  Gatekeeper
TP53  17p13  53 kDa phosphoprotein  Caretaker
PTEN  10q23.1  53 kDa phosphatase  Gatekeeper
BRCA1  17q21  220 kDa nuclear phosphoprotein  Caretaker
BRCA2  13q12  384 kDa nuclear phosphoprotein  CaretakerBiologics: Targets & Therapy 2007:1(3) 249
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of E2F deregulation, resulting in earlier recurrence (Bosco 
et al 2007).
TP53
The TP53 gene is located on chromosome 17p13 and spans 
20 kb (Macdonald et al 2004; Lacroix et al 2006; Schultz 
2006). It is composed of 11 exons, which encode for a 2.8 kb 
transcript. Its protein product, p53, is a 53 kDa phosphoprotein, 
although its calculated mass in around 44 kDa. It is generally 
found in the nucleus and has a rather short half-life of around 
20 minutes. p53 belongs to a protein family composed of two 
other proteins, p63 and p73, both of which share homology 
with p53 but have different functions. It is a transcriptional 
activator and exhibits a structure typical to other activators, 
with three domains. The amino terminal transactivation 
domain contains a relatively large number of acidic amino 
acids and proline-rich region, which is responsible for its 
apoptotic activity. The central core domain of p53 is highly 
conserved evolutionarily and is responsible for p53’s binding 
to promoters, during transcriptional activation. It is hydropho-
bic in nature and is folded into β sheets. The carboxy terminal 
domain contains many charged amino acids making it hydro-
philic in nature. It is responsible for forming p53 tetramers. It 
also contains three nuclear localization signals.
p53 is responsible for a variety of functions within the 
cell’s economy, including cell cycle arrest and promotion of 
apoptosis, DNA repair, cell differentiation, and inhibition of 
angiogenesis (Braithwaite et al 2005; Toledo and Wahl 2006; 
Vousden and Lane 2007). Its main function is to ensure that 
the cell’s genome remains intact before cell division occurs 
and because of this function it is often called the “Guard-
ian of the Genome” (Lane 1992). MDM2 (an ubiquitin 
ligase mouse double minute-2 homologue; called HDM2 
in humans) and MDM4, which bind to the amino terminus 
of p53, are responsible for inhibiting p53 and promoting its 
degradation (Haupt 2004). p53 also binds to genes such as 
BAX that are responsible for the apoptotic pathway, thereby 
shuttling the cell into programmed cell death. The p53 path-
way is generally activated by DNA damage, which results 
in phosphorylation of p53 by ATM or CHK2 at sites near 
MDM2 and MDM4 binding. MDM2 or MDM4 are released, 
and the CKI p21 then binds to p53 (Macdonald et al 2004). 
p21 is transactivated and arrests the cell cycle until the DNA 
is repaired. Mutations of p53 that disrupt this pathway result 
in cell division, even though its DNA is damaged. Such dam-
age can lead to carcinogenesis.
Alteration in TP53, usually in terms of missense muta-
tions is found in more than half of all cancers (Macdonald 
et al 2004; Braithwaite et al 2005). Around 20%–40% of 
breast cancers have a genetic or an epigenetic altered form 
of the TP53 gene, which is associated with poor prognosis 
(Gasco et al 2002; Børresen-Dale 2003; Macdonald et al 
2004). Usually, the genetic alteration is often a point muta-
tion that results in a malfunctioning, non-degradable protein 
that accumulates in tumor cells. Altered TP53 (exons 5–8) is 
generally associated with sporadic breast cancer; however, 
it may function as a susceptibility gene in patients suffering 
from Li-Fraumeni syndrome (Macdonald et al 2004; Lacroix 
et al 2006).
An increased rate of TP53 mutation is also associated 
with carriers of BRCA1 and BRCA2 germline mutations 
(Gasco et al 2002; Lacroix et al 2006). BRCA1 apparently 
stimulates transcription of TP53 since mutant forms of 
BRCA1 do not have the same activity levels. Apoptosis 
stimulating protein of p53 (ASPP) increases p53-dependent 
induction of apoptosis target genes, such as BAX (Gasco 
et al 2002). Finally, alteration of genes in the TP53 path-
way can also lead to breast cancer. For example, loss of the 
cell cycle checkpoint kinase CHK2 results in an inability 
to stabilize p53 (Osborne et al 2004). However, these 
mutations are much less common in breast cancer (Gasco 
et al 2002). Downregulation of this gene affords cells with 
damaged DNA a greater chance of surviving and dividing 
(Ingvarsson 2004).
TP53 and its regulation by MDM2 and MDM4, as 
well p53 itself, are targets for the development of rational 
cancer therapies (Braithwaite et al 2005; Bouchet et al 
2006; Lacroix et al 2006). The disruption of MDM2-p53 
and MDM4-p53 interactions is targeted through small 
molecular weight molecules, such as the nutlins, which 
are cis-imidazoline derivatives. Nutlins have yielded 
impressive results in xenografts by inhibiting tumor 
growth at high doses, with no obvious toxicity. Antisense 
oligonucleotides to the MDM2 gene have also been devel-
oped to downregulate the inhibitor, thereby increasing p53 
levels. In addition, MDM2 siRNA has been successfully 
used to inhibit p53-dependent breast cancer (Liu et al 
2004). Gene therapy to replace wild type TP53, using 
retroviruses and the adenovirus Ad5CMv-p53, has been 
developed to restore p53 functional levels. Finally, restor-
ing or rescuing aberrant p53 activity has proven a suc-
cessful therapeutic strategy (Takimoto et al 2002; Bossi 
and Sacchi 2007). For example, CP-31398 and PRIMA-1 
have been shown to rescue p53 activity by binding to 
defective p53 and then restoring its ability to function 
normally (Wang et al 2003). Moreover, these agents act Biologics: Targets & Therapy 2007:1(3) 250
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synergistically. For example, PRIMA-1 and cisplatin act 
synergistically to enhance tumor cell apoptosis (Bykov 
et al 2005).
PTEN
The PTEN (phosphatase and tensin homolog deleted on 
chromosome ten, also known as MMAC1 or TEP1) gene is 
located on chromosome 10q23.1 (Li et al 1997; Weng et al 
1999). It consists of nine exons and transcribes a 5.5 kb 
mRNA, which encodes for a 53 kDa protein (Kim and Mak 
2006). The PTEN protein contains a phosphatase domain 
at the amino terminal region, with a phosphatase motif 
(HCX(A/X)GXXR(S/T)G) that is common for both tyrosine 
and dual-speciﬁ  city (serine and threonine) phosphatases 
(Li et al 1997; Simpson and Parsons 2001). The catalytic 
region consists of a wider pocket than most phophatases and 
contains three positively charged amino acids that account 
for its preference for acidic substrates (Di Cristofano and 
Pandolﬁ   2000). The main substrate for the phosphatase is 
PIP3 (Maehama and Dixon 1999). The carboxy terminal 
region consists of a C2 domain that binds phospholipids 
and of a tail region that contains PEST sequences and CK2 
phosphorylation sites important for structural stability and 
catalytic activity (Simpson and Parsons 2001). Finally the 
tail region contains a PDZ domain that binds MAGI proteins, 
which are important for locating the phosphatase at the cell 
membrane.
PTEN functions in the cell’s economy through arrest-
ing the cell cycle and promoting cell apoptosis, as well as 
regulating cell adhesion, migration, and invasion especially 
through extracellular molecules like the integrins (Tamura 
et al 1999; Di Cristofano and Pandolﬁ   2000; Waite and Eng 
2002). The PTEN phosphatase acts as a TSG by dephos-
phylating PIP3, thereby downregulating AKT (also known 
as protein kinase B). Inhibition of AKT activation in turn 
downregulates the signal transducer or effector mTOR 
(mammalian target of rapamycin), which in turn leads to 
arrest of the cell cycle at G1 and to programmed cell death 
(Lu et al 1999; Guertin and Sabatini 2005; Bianco et al 
2006). Besides the cytoplasm, PTEN is also found in the 
nucleus and may function in not only downregulating the 
AKT/mTOR pathway but also other cellular pathways like 
CENP-C and RAD51 pathways that are important in chro-
mosome integrity (Chung et al 2006; Baker 2007). Finally, 
PTEN is also involved in the downregulation of cyclin D1 
through the MAPK pathway.
PTEN is involved in germ-line mutations that are 
responsible for Cowden and Bannayan-Riley-Ruvalcaba 
syndromes, in which 80% of the tumors arising in these 
syndromes are present in the breast (Liaw et al 1997; Marsh 
et al 1998; Lu et al 1999). Loss of PTEN is associated 
with aggressive breast malignancy and poor prognosis 
(Garcia et al 1999; Petrocelli and Slingerland 2001). 
PTEN in Cowden breast cancer is chieﬂ  y mutated within 
the amino terminal phosphatase domain, while PTEN in 
Bannayan- Riley-Ruvalcaba breast cancer is mutated in 
the non-phosphate domains (Rhei et al 1997; Marsh et al 
1998; Waite and Eng 2002). Loss of PTEN is also prevalent 
in sporadic breast cancer, although mutation of the gene 
is infrequent and methylation of the PTEN promoter is 
responsible for inhibiting PTEN gene expression (Khan 
et al 2004). Although PTEN is involved in regulation of 
the P13K/AKT/mTOR pathway in breast carcinogenesis, 
recent evidence suggests that its regulation is more com-
plex (deGraffenried et al 2004; Panigrahi et al 2004; Bose 
et al 2006).
PTEN and the P13K/AKT/mTOR pathway provide 
useful targets for developing robust therapies for breast 
cancer (Lu et al 2003; Kim et al 2005). There has been little 
work done to target PTEN until recently. Reconstitution 
studies with PTEN gene therapy in a mouse model for lung 
cancer, for example, reveals that apoptosis is increased, 
while AKT and mTOR activation is decreased signiﬁ  cantly 
(Kim et al 2005). In addition, antisense oligonucleotides 
to PTEN resulted in trastuzumab resistance, while rescue 
of PTEN through P13K inhibitors restored trastuzumab 
sensitivity (Nagata et al 2004). Recently, Par-4 has been 
shown to participate in PTEN-mediated apoptosis and 
may provide a useful target for therapeutic development 
(Goswami et al 2006).
A number of inhibitors have been developed to key 
components of the P13K/AKT/mTOR pathway (Chen 
et al 2005; Granville et al 2006). P13K inhibitors target 
the p110 ATP binding site in the catalytic pocket. The two 
best known inhibitors are LY294002 and wortmannin, 
which in combination is more effective than either alone 
and exhibits fewer toxicities. AKT inhibitors exhibit a 
variety of mechanisms, including translocation inhibition 
and binding to the catalytic or substrate binding sites. 
Examples of these inhibitors include perifosine, PX-316, 
and NL-71-101. The most studied inhibitors are those for 
mTOR and include rapamycin and its derivatives CCI-779, 
RAD-001, and AP-23573 (Vignot et al 2005; Tsang et al 
2007). Phase II trials with CCI-779 demonstrated its safety 
for treating advanced and metastatic breast cancer (Chan 
et al 2002). Recently, a multicenter randomized phase II Biologics: Targets & Therapy 2007:1(3) 251
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trial suggests that oral administration of 10 mg daily of 
RAD-001 is also efﬁ  cacious in metastatic breast cancer 
patients (Ellard et al 2007).
BRCA1 and BRCA2
The tumor susceptibility genes, BRCA1 and BRCA2, are 
found in about 80% of familial breast cancer cases and only 
5%–10% of all breast cancer cases (Rosen et al 2003; Antoniou 
and Easton 2006). BRCA1 and BRCA2 are considered high-
penetrance variants, especially in some ethnic groups like 
Ashkenazi Jews, with as high as 90% penetrance – although 
there is evidence to indicate that the estimates over-represent 
the penetrance by about a half (Begg 2002; Macdonald et al 
2004). In general the risk of developing breast cancer increases 
with age, but due to nongenetic factors the age of onset can 
vary widely (Osborne et al 2004). However, among those who 
carry BRCA1 or BRCA2 mutations, the risk of developing 
cancer not only increases with age but the age of onset is 
markedly earlier (Macdonald et al 2004). Both BRCA1 and 
BRCA2 are caretaker genes and are important in maintaining 
the integrity of the cell’s genome (Venkiteraman 2002; 
Iggvarsson 2004; Macdonald et al 2004).
BRCA1 is located on chromosome 17q21 and contains 
24 exons, 22 of which encode for a 220 kDa nuclear 
phosphoprotein (Nathanson et al 2001; Macdonald et al 
2004; Schulz 2006). Exon 11 alone accounts for around 
50% of the encoding gene. The BRCA1 protein exhibits 
several structure domains important for its function (Rosen 
et al 2003). At the amino terminus is a zinc-binding RING-
ﬁ  nger domain, containing a cys3-his-cys4 structure, which 
binds BARD1 (BRCA1-associated RING domain protein) 
and BAP1 (BRCA1-associated protein) – hallmarks of the 
RING-ﬁ  nger family of transcriptional regulatory proteins. 
The domain also binds other proteins, including cyclin D1, 
ERα, and c-MYC. The carboxy terminus contains two 110 
amino acid sequence BRCT (BRCA C terminal) domains 
that are involved in transcription activation and for binding 
proteins critical for that function, like histone deactylase. 
Finally, BRCA1 has a central domain that binds proteins 
involved in repair of double-strand DNA breaks. BRCA1 
mutations are usually frame-shift mutations that result in a 
truncated protein, but point mutations can occur at both the 
amino and carboxy termini.
The BRCA1 protein is part of a genome surveillance 
complex (BASC) that is composed of DNA repair and TSG 
proteins, such as MSH2 and the RAD50-MRE11-p95 com-
plex, which are involved in recombination-mediated repair 
of double-stranded DNA breaks (Nathanson et al 2001; 
Macdonald et al 2004; Gudmundsdottir and Ashworth 2006). 
The BRCA 1 gene is transcribed during late G1 phase and 
throughout the S phase (Macdonald et al 2004). Following 
DNA damage, ATM, ATR, or CHK2, regulator proteins in 
pathways of tumor cell suppression, rapidly phosphorylate 
BRCA1 to an active state (Gasco et al 2002; Gudmundsdottir 
and Ashworth 2006). BRCA1 stops the cell cycle at the S 
and G2/M checkpoints, points before cell division (Rosen 
et al 2003; Deng 2006). In general, BRCA1 inhibits the 
activity of oncogenes and ampliﬁ  es the activity of TSGs 
(Rosen et al 2003). For example, it can bind and inhibit 
c-MYC or it can transactivate both p21 and p27 (Rosen et al 
2003). BRCA1 can also bind directly to p53, enhancing its 
transcriptional ability and stabilizing its protein (Gasco et al 
2002). Finally, it also functions in chromatin remodeling 
and is required for centromere replication (Rosen et al 2003; 
Osborne et al 2004).
The BRCA2 gene is located on chromosome 13q12 and 
contains 27 exons, 26 of which encode for a 384 kDa nuclear 
phosphoprotein (Nathanson et al 2001; Macdonald et al 2004; 
Schulz 2006). Like BRCA1, BRCA2’s exon 11 accounts for 
half of the coding gene; and, its exon 10 is relatively large 
compared to other exons. BRCA2 is somewhat structurally 
similar to BRCA1 but does not contain as many well deﬁ  ned 
structural domains as BRCA1 (Nathanson et al 2001). The 
amino terminus contains transcriptional activation domains, 
while the carboxy terminus contains a nuclear localization 
signal that is involved in shuttling the recombinase RAD51 
from the cytoplasm to the nucleus (Venkitaraman 2002; 
Gudmundsdottir and Ashworth 2006). The central domain 
contains eight copies of the ~40 amino acid BRC repeat, which 
are responsible for binding RAD51. BRCA1 and BRCA2 are 
thought to be co-regulated during the cell cycle and DNA 
repair (Rosen et al 2003; Macdonald et al 2004). They, along 
with RAD51, BARD1 and other components, form the BRCC 
complex that is critical for double-strand DNA break repair 
(Gudmundsdottir and Ashworth 2006).
The BRCA susceptibility genes afford clinical investi-
gators several strategies for targeted therapy (Yarden and 
Papa 2006). One strategy is to target histone deacetylase, 
which is involved in chromosome integrity. BRCA1, as 
noted above, binds and regulates the deacetylase from com-
promising chromosome integrity. Inhibitors to the enzyme 
would compensate for breast tumors that do not express 
BRCA1. Another strategy is to inhibit poly(ADP-ribose) 
polymerase 1 (PARP1), an enzyme involved in repair of 
breaks in DNA. Recent studies demonstrate that breast 
cancer cells deﬁ  cient in BRCA genes are three orders of Biologics: Targets & Therapy 2007:1(3) 252
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magnitude more sensitive than normal breast cells to PARP1 
inhibitors, resulting in the induction of cell programmed 
death because chromosomal DNA breaks are not repaired 
(Bryant et al 2005; Farmer et al 2005; Turner et al 2005).
The next strategy focuses on BRCA replacement gene 
therapy. Studies have shown that reintroduction of BRCA 
genes into breast cancer cells have resulted in cell cycle arrest 
and apoptosis (Osborne et al 2004; Stoff-Khalili et al 2006). 
Another strategy involves BRCA1 overexpression in a breast 
cancer cell line, which confers resistance to chemotherapy. 
Utilization of BRCA1 antisense oligonucleotides restored 
drug sensitivity (Husain et al 1998). Finally, second gen-
eration platinum-based chemotherapeutics is being actively 
perused to treat cancer patients (Kelland 2007). For example, 
a phase II clinical trial with carboplatin is currently underway 
(BRCA trial 2007).
Challenges
The challenges for the genetic approach to breast cancer 
involve both greater understanding of the underlying molecu-
lar mechanisms for breast carcinogenesis and more effective 
and speciﬁ  c treatment regimes, as well as prevention of the 
disease. As for the underlying molecular mechanism, a fuller 
understanding of the pathways and of the genes that constitute 
those pathways are required. For example, ten genes have 
been identiﬁ  ed for inherited breast cancer cases; but, they 
only account for 50% of the cases (Walsh and King 2007). 
The genes responsible for the other half of inherited breast 
cancer cases are unresolved. Another important factor for 
understanding breast cancer development is the tumor’s 
microenvironment, which also plays a signiﬁ  cant role in 
tumor initiation and progression (Liotta and Kohn 2001; 
Wiseman and Werb 2002). The microenvironment is no lon-
ger considered an “innocent bystander” that passively serves 
as scaffolding for carcinogenesis (Erickson and Barcellos-
Hoff 2003). Rather, an altered microenvironment or terrain is 
a common feature of cancer and it is thought to induce malig-
nant transformation of the surrounding epithelium through 
oncogenic pathways (Comoglio and Trusolino 2005). These 
“landscaper” defects reﬂ  ect alterations in genes responsible 
for the microenvironment’s composition and architecture 
(Kinzler and Vogelstein 1998; Alessandro et al 2004).
Chow et al (2006) have identified three challenges 
for breast cancer therapy research. The ﬁ  rst involves the 
improvement of the efficacy for conventional chemo-
therapy. Especially the use of combinatorial strategies is 
required to optimize a therapeutic regime, and yet keep 
toxicities at a minimum. The next challenge is to develop 
targeted therapeutic protocols for many of the known genes 
responsible for breast cancer development, especially in 
terms of gene therapy, and to incorporate them into pres-
ent protocols or to develop new ones. Moreover, what is 
required is not an additive but a synergistic effect between 
different drugs. Such synergism insures that the therapeutic 
protocol is optimally effective and minimally harmful to the 
patient. The development of cancer is a complex phenomenon 
that requires a number of genes and molecular pathways. 
In essence, the disease is a synergistic interplay of genes 
and pathways and only a combination of drugs that targets 
these genes and pathways will be effective. It is doubtful if 
there is a “magic bullet” therapy for many types of cancer, 
including breast cancer. In addition, there is the need for 
the discovery of new genes and genes products to target for 
therapeutic regimes. The ﬁ  nal challenge is the development 
of better methods for categorizing breast cancer heteroge-
neity, as well as better means to predict drug response and 
resistance. Pharmacogenetics and DNA microarray analysis 
are already being employed to provide more accurate clas-
siﬁ  cation of breast cancer types and response of patients to 
drugs (Lønning et al 2005; Espinosa et al 2006; Marsh and 
McLeod 2007).
Besides these challenges there are two additional ones: 
cancer stem cells (CSCs) and prevention. Although the 
idea of CSCs is an old one it has only been within the past 
decade that it has been supported experimentally (Clarke 
et al 2006; Dean 2006; Massard et al 2006; Witcha et al 
2006), even though there are some theoretical and techni-
cal concerns in terms of its application to solid tumors like 
breast cancer (Hill 2006). The traditional stochastic model 
claims that any cell can become tumorigenic, while the 
hierarchical model or cancer stem cell hypothesis claims 
that only a subset of tumor-initiating cells is responsible for 
tumorigensis (Dick 2003). The cancer stem cell hypothesis 
has important implications for therapy. Instead of treating 
proliferating cells, which can only result in limited tumor 
remission with possible recurrence, elimination of the CSCs 
would effectively remove the cancer. Recently CSCs, rep-
resenting about 2% of the cells, were isolated from human 
breast cancer tissue and produced tumors upon injection 
into immunodeﬁ  cient mice (Al-Hajj et al 2003). Moreover, 
these cells have been grown in vitro (Ponti et al 2005, 2006). 
The challenge for breast cancer treatment is to target breast 
CSCs and their unique components thereby permitting their 
complete destruction.
The second challenge for breast cancer research is pre-
vention in terms of medical management for early onset of Biologics: Targets & Therapy 2007:1(3) 253
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the disease and with respect to lifestyle factors. Medical 
management vis-à-vis prevention, especially of inherited 
breast cancer, includes procedures such as early detection of 
breast cancer by imaging techniques, chemoprevention, and 
prophylactic surgical procedures (Pruthi et al 2007; Robson 
and Ofﬁ  t 2007). Early detection of breast cancer is important 
in terms of its prevention, especially since it metastasizes 
rather quickly. Although the sensitivity of traditional mam-
mography is around 85%, it is not as sensitive (38%–55%) for 
women with dense breasts or BRCA mutations (Kerlikowske 
et al 1996; Scheuer et al 2002; Pruthi et al 2007). This means 
that there is still a considerable number of false negatives, 
even for traditional imaging techniques. Although new imag-
ing technology is being developed, such as digital mammogra-
phy, ultrasound, and MRI, appropriate clinical trials have yet 
to be conducted to test them (Elmore et al 2007).
A number of prospective, randomized, placebo-controlled 
clinical trials have been conducted recently in terms of 
chemoprevention, especially with the ﬁ  rst-generation SERM 
tamoxifen and the second-generation SERM raloxifene 
(Cuzick et al 2003; Vogel 2007). The results from these 
studies, although encouraging, have been mixed. From 
the four trials, Royal Marsden, NSBP P-1, Italian, and 
IBIS-I, the total number of breast cancers developed from 
the tamoxifen-treated group was 289 out of 14,192 woman, 
while for the placebo-controlled group it was 465 out of 
14,214 women. This represents an average of 38% for the 
reduction of breast cancer incidence, with a range from 
17%–49%. The STAR study, which was recently completed, 
compared tamoxifen to raloxifene and found that the second-
generation SERM was as effective as the ﬁ  rst generation 
SERM and exhibited less pronounced side effects like bone 
fractures and thromboemboli. Aromatase inhibitors (AIs) 
are currently being tested in two international clinical trials 
(O’Regan 2006). The use SERMs or AIs are effective against 
the incidence of ER-positive breast tumors. Future research 
must address the prevention of ER-negative tumors.
Besides chemoprevention, surgical procedures have been 
also developed to prevent the incidence of breast cancer in 
high risk women, especially BRCA mutation carriers. The 
ﬁ  rst is bilateral prophylactic or risk-reducing mastectomy. 
The PROSE study found that this surgical procedure reduced 
the risk of breast cancer by 90% for women with intact ova-
ries and by 95% for women without ovaries (Rebbeck et al 
2004). To date, there has not been a randomized controlled 
clinical trial to conﬁ  rm the beneﬁ  t of the procedure (Zakaria 
and Degnim 2007). The major problem with this procedure 
is its acceptance among high risk women, which requires 
sociological and psychological studies (Lynch et al 2001). 
Another more acceptable surgical procedure – because of 
self-image issues – is prophylactic or risk-reducing salpingo-
oophorectomy, which reduces the risk of breast cancer by 
about 50% (Kauff and Barakat 2007). The major problem 
with this procedure is the use of hormones to manage post 
salpingo-oophorectomy, which may increase the risk of 
breast cancer incidence.
Lifestyle factors, including body size and composition, 
diet, and exercise, are important factors in breast cancer 
prevention (Brody et al 2007; Michels 2007). For example, 
maintaining one’s “ideal” body weight (BMI = 19–25 kg/m2) 
and engaging in moderate exercises reduces the risk of breast 
cancer by about 30% (Pruthi et al 2007). Interestingly, diet, 
especially in terms of a low-fat and high in vegetables, fruit, 
and ﬁ  ber diet, does not reduce the risk of breast cancer for 
women with treated early-stage breast cancer (Pierce et al 
2007). However, the role of diet on the incidence of breast 
cancer requires further investigation with respect to long term 
studies, especially for women who are at risk for the disease. 
In addition, even though alcohol consumption, cigarette 
smoking, and exposure to environmental carcinogens are 
known risk factors for breast cancer, there is still much that 
needs to be investigated in terms of lower risk patients. In 
conclusion, although the nature of breast cancer is better 
understood today than several decades ago there is still much 
more basic and clinical research needed before the disease is 
controlled and hopefully someday eradicated.
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